secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001193125-25-271112
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q3 net loss improves to $0.41/share; highlights evorpacept benefit in CD47-high gastric cancer
--------------------------------------------------------------------------------

- GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.
- Cash, cash equivalents and investments at Sept 30, 2025: $66.5M; runway into Q1 2027.
- ASPEN-06 exploratory analysis: In CD47-high retained HER2+ gastric cancer, evorpacept combo achieved 65.0% ORR vs 26.1% for control; median DOR 25.5 vs 8.4 months.
- Phase 1 ALX2004 (EGFR-targeted ADC) cleared first dose cohort; currently enrolling 2 mg/kg dose; initial safety data expected 1H 2026.
- Barbara Klencke, M.D., appointed interim Chief Medical Officer; brings 30+ years oncology drug development experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/0001193125-25-271112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/alxo-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-271112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer